A quinazolinone compound and application thereof

By developing quinazolinone compounds to target and inhibit PI3Kδ and HDACs, the adverse reaction problems of existing drugs have been solved, achieving significant anti-tumor activity and reduced side effects, and showing broad clinical application prospects.

CN122404294APending Publication Date: 2026-07-17ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202610852109.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-06-12
Publication Date
2026-07-17

AI Technical Summary

Technical Problem

Existing PI3Kδ inhibitors and HDAC inhibitors have adverse effects such as short in vivo half-life, strong cytotoxicity, and cardiotoxicity, which limits the application of single-target anticancer drugs. Furthermore, there is a lack of quinazolinone dual-target antitumor drugs that have both PI3Kδ and HDACs inhibitory activities.

Method used

A quinazolinone compound was developed, and biological experiments demonstrated that it can simultaneously target and inhibit PI3Kδ and HDACs, forming a synergistic anti-tumor regulatory mechanism and reducing side effects.

Benefits of technology

It achieved significant anti-tumor activity while reducing drug side effects, and has good application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_20
    Figure SMS_20
  • Figure SMS_22
    Figure SMS_22
Patent Text Reader

Abstract

本发明属于药物化学领域，具体涉及一种如式I‑III所示的喹唑啉酮类化合物或其药学上可接受的盐或氘代物及其应用。经生物实验证实，该类化合物同时靶向抑制PI3Kδ和HDACs，在具有显著的抗肿瘤活性的同时有望降低副作用，可作为PI3Kδ / HDACs双重抑制剂用作肿瘤及其他PI3Kδ / HDACs相关疾病的治疗，具有良好的应用前景。
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • PI3K / HDAC dual inhibitor and application thereof

    CN117736192A